Literature DB >> 1373021

SP-40,40 is a constituent of Alzheimer's amyloid.

N H Choi-Miura1, Y Ihara, K Fukuchi, M Takeda, Y Nakano, T Tobe, M Tomita.   

Abstract

Cerebrospinal fluid (CSF), serum and seminal plasma contain a small amount of SP-40,40, a modulatory protein of the human complement system. The SP-40,40 in each body fluid was different in molecular size on SDS-PAGE, and glioblastoma cells, hepatoma cells and testicular tumor cells produced SP-40,40, while neuroblastoma cells did not. Therefore, it was estimated that CSF SP-40,40 originated in glia cells, serum SP-40,40 in liver cells and seminal plasma SP-40,40 in testicular cells. SP-40,40 concentrations in CSF of the patients with Alzheimer's disease and the patients with cerebral tumor were higher than those of normal donors. beta-Amyloid deposits in the brains of the patients with Alzheimer's disease were stained with an anti-SP-40,40 monoclonal antibody (mAb) but not with an anti-S-protein mAb, while cellular processes around beta-amyloid were stained with an anti-S-protein mAb but not with an anti-SP-40,40 mAb. Therefore, beta-amyloid contained SP-40,40 in a form different from that in the soluble membrane attack complex (SMAC, SC5b-9) of the complement, which contains S-protein as well as SP-40,40.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373021     DOI: 10.1007/bf00296787

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  20 in total

1.  SP-40,40 is an inhibitor of C5b-6-initiated haemolysis.

Authors:  B F Murphy; J R Saunders; M K O'Bryan; L Kirszbaum; I D Walker; A J d'Apice
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

2.  Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.

Authors:  D E Jenne; J Tschopp
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Changes in brain gene expression shared by scrapie and Alzheimer disease.

Authors:  J R Duguid; C W Bohmont; N G Liu; W W Tourtellotte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis.

Authors:  F Coria; E Castaño; F Prelli; M Larrondo-Lillo; S van Duinen; M L Shelanski; B Frangione
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

Authors:  P Eikelenboom; F C Stam
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

7.  Preparation and fractionation of glycopeptides.

Authors:  J Finne; T Krusius
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

8.  Sulfation of two tyrosine-residues in human complement S-protein (vitronectin).

Authors:  D Jenne; A Hille; K K Stanley; W B Huttner
Journal:  Eur J Biochem       Date:  1989-11-06

9.  Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells.

Authors:  M W Collard; M D Griswold
Journal:  Biochemistry       Date:  1987-06-16       Impact factor: 3.162

10.  Purification and characterization of a sulfated glycoprotein secreted by Sertoli cells.

Authors:  M D Griswold; K Roberts; P Bishop
Journal:  Biochemistry       Date:  1986-11-18       Impact factor: 3.162

View more
  30 in total

1.  V-src-induced-transcription of the avian clusterin gene.

Authors:  Y Herault; G Chatelain; G Brun; D Michel
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

2.  Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Authors:  Jose Morales-Corraliza; Stephen D Schmidt; Matthew J Mazzella; Jason D Berger; Donald A Wilson; Daniel W Wesson; Mathias Jucker; Efrat Levy; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2012-05-18       Impact factor: 4.673

3.  Increase in clusterin-containing follicles in the adenohypophysis of drug abusers.

Authors:  Takaki Ishikawa; Bao-Li Zhu; Satoru Miyaishi; Hideo Ishizu; Hitoshi Maeda
Journal:  Int J Legal Med       Date:  2006-11-18       Impact factor: 2.686

4.  Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies.

Authors:  K Nishida; A J Quantock; A Dota; N H Choi-Miura; S Kinoshita
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

Review 5.  Microglial dysfunction in brain aging and Alzheimer's disease.

Authors:  Kira Irving Mosher; Tony Wyss-Coray
Journal:  Biochem Pharmacol       Date:  2014-01-18       Impact factor: 5.858

Review 6.  The toxicity in vitro of beta-amyloid protein.

Authors:  L L Iversen; R J Mortishire-Smith; S J Pollack; M S Shearman
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

7.  Potential role of apolipoprotein-E in fibrillogenesis.

Authors:  G Gallo; T Wisniewski; N H Choi-Miura; J Ghiso; B Frangione
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Authors:  Valerie Yu; Dhruva Bhattacharya; Andrew Webster; Aditi Bauskar; Charles Flowers; Martin Heur; Shravan K Chintala; Tatsuo Itakura; Mark R Wilson; Joseph T Barr; Shinwu Jeong; Mingwu Wang; M Elizabeth Fini
Journal:  Ocul Surf       Date:  2018-08-02       Impact factor: 5.033

9.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

Review 10.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.